Key Takeaways ESTA submitted Motiva implants to the FDA for primary and revision breast reconstruction.ESTA aims to expand Motiva beyond elective augmentation into reimbursement-backed reconstruction care.ESTA's filing is backed by a 274-patient IDE study across 17 U.S. sites and one in Europe.Establishment Labs (ESTA) recently announced that it has submitted its Motiva breast implants to the FDA for approval in primary and revision breast reconstruction. The filing builds on the company’s September 2024 FD ...